A Case of Pneumatosis Cystoides Intestinalis after Erlotinib-containing Chemotherapy for Pancreatic Cancer.
10.15279/kpba.2016.21.3.156
- Author:
Ga Young KIM
1
;
Min Keun KIM
;
Dong Wook LEE
;
Jimin HAN
;
Ho Gak KIM
Author Information
1. Department of Internal Medicine, Catholic University of Daegu School of Medicine, Daegu, Korea. dwlee@cu.ac.kr
- Publication Type:Case Report
- Keywords:
Pancreatic cancer;
Erlotinib;
Pneumatosis cystoides intestinalis
- MeSH:
Abdominal Pain;
Aged;
Drug Therapy*;
Drug Therapy, Combination;
Erlotinib Hydrochloride;
Female;
Humans;
Neoplasm Metastasis;
Pancreatic Neoplasms*;
Physical Examination;
Pneumatosis Cystoides Intestinalis*
- From:Korean Journal of Pancreas and Biliary Tract
2016;21(3):156-162
- CountryRepublic of Korea
- Language:English
-
Abstract:
Pneumatosis cystoides intestinalis (PCI) is an uncommon condition that is characterized by the presence of gas within the bowel wall. We experienced a case of PCI after erlotinib-containing chemotherapy for advanced pancreatic cancer. A 66-year-old woman was admitted to the hospital with intermittent epigastric pain, and she diagnosed with advanced pancreatic cancer accompanied by hepatic metastasis. Combination chemotherapy of gemcitabine and erlotinib was started. PCI occurred about 14 months after start of the chemotherapy but she did not complain of abdominal pain and physical examination showed no evidence of peritoneal irritation sign. Laboratory findings showed no abnormalities. Following conservative treatment for 3 days, no specific symptoms were observed, and abdominal X-ray examination showed reduced abnormal air deposition. Erlotinib-containing chemotherapy was continued and PCI had not recurred.
